JNJ-2901
JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. JNJ-2901 reduces bacterial load in the acute/chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 can be used in tuberculosis (TB) research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2059985-55-4
- 分子式: C24H24ClF3N4O3S
- 分子量:540.99
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
JNJ-2901 (0.005 µM-5 mM, 5 d) inhibits the growth of M. tuberculosis H37Rv-ΔcydAB in 7H9 medium (MIC50: 2.5 nM)[1].
JNJ-2901 inhibits oxygen consumption by the wild-type strain (IC50: 89 nM) and the cytochrome bd knockout strain (ΔcydAB) (IC50: 60 nM) of M. smegmatis, but has no significant effect on the cytochrome bc knockout strain (ΔqcrCAB)[1].
JNJ-2901 inhibits oxygen consumption by M. smegmatis cytochrome bcMtb-like (IC50: 17.4 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute/chronic mouse model infected with M. tuberculosis H37Rv-ΔcydAB, 6-8 weeks old female Balb/cBy mice[1].
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection (s.c.), 12 d for acute infection and 8 weeks for chronic infection
-
Result:Reduced bacterial load in an acute infection model in mice (3.6-log) and in a chronic infection model (4.0-log).
化学情報
-
CAS 番号 2059985-55-4
-
分子量 540.99
-
分子式 C24H24ClF3N4O3S
-
SMILES
CCC1=C(N2C=C(C=CC2=N1)Cl)C(NCC3=CC=C(C=C3)C4CC5(CN(C5)S(=O)(C(F)(F)F)=O)C4)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
JNJ-2901 関連分類
HY-172349 関連分類
Powered by Bioz